Bristol-Myers Squibb’s Revenue by Region (2016-2023)

This statistic highlights Bristol-Myers Squibb’s Revenue by Region, split between Europe, the United States, and the Rest of the World.

Bristol-Myers Squibb Corporation is an American pharmaceutical company, which produces and sells prescription pharmaceuticals and biologics in several therapeutic areas. It is headquartered in New York, USA.

Bristol-Myers Squibb’s Revenue by Region

(All figures in billions)

An analysis of the region-wise revenue of the company is discussed below.

United States

A majority of Bristol-Myers Squibb’s revenue comes from the United States, which contributed about 65% of total revenue in Q1 2021  amounting to $7.01 billion. There was a 3.5% increase in revenue compared to Q4 2020 where the revenue generated was $6.78 billion. Further, there was a 3% increase as compared to Q1 2020, when $6.77 billion was earned. This region’s revenue has steadily increased from $6.49 billion in Q2 2020 to $7.01 billion in Q1 2021.

In this region, the company has its R&D plants in New Jersey, New York, and California.

Europe

Europe contributed about 23% of the company’s total revenue in Q1 2021. There was a 5% decrease in the company’s revenue from this region, from $2.70 billion in Q4 2020 to $2.55 billion in Q1 2021. This also corresponded to a 0.7% decrease compared to Q1 2020, where the company earned $2.57 billion.

In Europe, the company operates in the United Kingdom, France, Belgium, Ireland, Germany

Rest of the World

This region contributed 12% of the total revenue in Q1 2021. Its revenue fell from $1.43 billion in Q4 2020 to $1.35 billion in Q1 2021, which is a decrease of 6%. But there was a 0.7% increase compared to Q1 2020 when $1.35 billion was earned. Bristol-Myers Squibb has its facilities in countries such as India, Japan, Canada, and China.

The company’s total revenue has been steadily increasing from $9.96 billion in Q2 2020 to $10.91 billion in Q1 2021, which is a 9% increase. The reason for this increase is due to the rise in demand for medicines such as Orencia, Revlimid, Opdivo, Sprycel, Eliquis, Zeposia, Imnovid, Yervoy, Abraxane, Empliciti, Reblozyl, and Onureg during the Covid-19 pandemic. The revenues are expected to increase further with the introduction of new medicines such as Beclabuvir, Elotuzumab, Lirilumab, BMS-9060204, BMS-955176, Brivanib Alanine, and Lulizumab Pegol which are presently under development.

Company Overview

Bristol-Myers Squibb is a public limited company, founded by William Mclaren Bristol, E.R. Squibb, and John Ripley Myers, in 1887.  They deal in pharmaceutical products for diseases such as Cardiovascular diseases, Oncology, Diabetes mellitus, infectious diseases, including HIV infection and associated conditions, Psychiatry, Rheumatic disorders, Inflammatory disorders, and Transplant rejection. Bristol-Myers Squibb Corporation’s key managerial persons are Giovanni Caforio (M.D., Chairman and CEO), and Charles Bancroft(CFO). As of 2019, the number of employees of the company worldwide was 30,000. The common stocks of Bristol-Myers Squibb are listed on the New York Stock Exchange under the trading symbol “BMY”. The competitors of Bristol-Myers Squibb are Perrigo Company, Eisai, Pfizer, Mega We Care, Apotex, Abbott Laboratories, ConvaTec, and GlaxoSmithKline. This company is consistently ranked on the Fortune 500 list and is one of the world’s largest pharmaceutical companies.

Did you like Bristol-Myers Squibb’s Revenue by Region statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.